Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

AMRI Realigns Its Discovery Services

by Ann M. Thayer
December 10, 2012 | A version of this story appeared in Volume 90, Issue 50

Albany Molecular Research Inc. will fold its in vitro biology capabilities into its other drug discovery services. In the process, the firm will close its Bothell, Wash., site, which employs 24 people, by March 2013. The company will move most of the site’s activities to its Singapore location and certain analytical capabilities to its Albany headquarters. Earlier this year, AMRI trimmed its U.S. contract drug discovery staff, closed a site in Hungary, and expanded in India and Singapore.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.